Cyclica collaborates with Enamine to use REAL technology in its ligand design platform for AI-augmented drug design

The companies aim to empower Cyclica’s patented, evolutionary algorithm with new design options based on the 73,000 Enamine’s in-stock building blocks and 171 thoroughly validated synthesis procedures. The joint effort is expected to enable Cyclica’s Ligand Design to identify novel molecules with desired polypharmacological properties out of over 11 billion REAL (readily accessible) compounds. At least 80% of these compounds will be synthesized by Enamine within only 3-4 weeks.

Molecules produced by computers are frequently criticized by chemists who fail to find cost-efficient synthesis pathways to them or even question their existence because of e.g. stability issues. Enamine has changed the paradigm in accessing compounds for screening. Because of seamless control of resources (all building blocks need to be in stock at Enamine) and statistical knowledge-based enumeration of the virtual compound libraries, the REAL compounds are supplied as if they are from stock.

Cyclica’s Ligand Design technology will smartly generate REAL compounds on the fly which are predicted to bind to one or multiple targets, avoid anti-targets, and have desired ADMET and physicochemical properties, making them excellent future drug candidates. By traversing REAL space using a genetic sampling algorithm, a much larger chemical space can be accessed than is possible with conventional compound databases, leading to better candidate molecules.

Dr. Andrii Buvailo, Head of E-commerce at Enamine, commented “the REAL technology opens up access to large unexplored territory in the chemical universe of small molecules which are delivered to the bench almost like from stock. It has become a reference among our clients when it comes to virtual screening initiatives.” Michael Bossert, Head of Strategic Alliances at Enamine added: “Considering the rapidly evolving field of computational methods and techniques of Artificial Intelligence, such as machine learning and deep learning in virtual screening, we are pleased to enrich Cyclica’s approach, conveying in this manner a powerful new toolkit and pool of compounds to the early drug discovery community.”

“Bringing together Enamine’s REAL technology and Cyclica’s Ligand Design will allow our partners to obtain truly novel molecules without paying the cost of de novo synthesis, greatly increasing the speed and efficiency of drug discovery efforts,” said Dr. Andreas Windemuth, Chief Science Officer at Cyclica.

Source: Company Press Release